参芪扶正注射液辅助治疗肺癌合并阻塞性肺部感染的疗效及对血清PCT与hs-CRP及MMP-9的影响

Effects of Shenqi Fuzheng injection for the treatment of patients with lung cancer and obstructive pulmonary infections and its effects on serum PCT,hs-CRP and MMP-9

目的探究参芪扶正注射液辅助治疗肺癌合并阻塞性肺部感染患者的疗效及对血清降钙素原(PCT)、超敏C-反应蛋白(hs-CRP)及基质金属蛋白酶-9(MMP-9)含量的影响。方法选取2015年1月-2016年12月医院收治的120例肺癌合并慢性阻塞性肺部感染患者为研究对象,将患者分为试验组和对照组,每组60例;对照组采取呼吸机辅助治疗,同时进行常规的肺癌合并阻塞性肺部感染的治疗;试验组在对照组治疗的基础上,给予参芪扶正注射液;观察记录两组患者机械通气的情况,治疗前后肺功能及血气指标情况和血清中PCT、hs-CRP及MMP-9的含量及治疗期间的疗效和不良反应。结果试验组患者的总有效率为98.33%高于对照组86.67%(P<0.05);与对照组相比,试验组患者行机械通气的时间、脱机再上机率及入住ICU的时间减少,脱机成功率增加(P<0.05);治疗后,两组患者的FEV1、FEV1/FVC及MVV值均增加(P<0.05);试验组患者肺功能指标FEV1、FEV1/FVC及MVV的值分别为(1.81±0.51)L、(71.08±8.57)%、(75.14±5.82)(L/min)较对照组增加(P<0.05);治疗后,两组患者的PaO_2和pH均升高,PaCO_2均降低(P<0.05);试验组患者PaO_2、PaCO_2及pH值分别为(73.48±7.51)mmHg、(56.81±6.43)mmHg和(7.61±0.50),PaO_2和pH值高于对照组(P<0.05);PaCO_2低于对照组(P<0.05);接受治疗后,两组患者血清中PCT、hs-CRP及MMP-9含量均有下降(P<0.05);试验组血清中PCT、hs-CRP及MMP-9含量分别为(0.57±0.08)μg/L,(13.21±3.02)mg/L及(0.30±0.04)μg/L低于对照组(P<0.05);在接受治疗期间,两组患者均未出现严重不良反应,试验组患者出现1例轻微腹痛,1例腹泻;对照组患者出现2例胸闷。结论参芪扶正注射液辅助治疗肺癌合并阻塞性肺部感染的临床效果较好,且能降低患者血清中PCT、hs-CRP及MMP-9的浓度。

OBJECTIVE To investigate the effects of Shenqi Fuzheng injection on the treatment of lung cancer pa- tients with obstructive pulmonary infections and the effects on serum PCT, hs-CRP and MMP-9. METHODS From Jan. 2015 to Dec. 2016, 120 patients with lung cancer and chronic obstructive pulmonary infection were enrolled in this study. Patients were divided into observation group and control group, with 60 cases in each group. The con- trol group was treated with ventilator adjuvant therapy and treated with conventional lung cancer and obstructive pulmonary infection. The observation group was given Shenqi Fuzheng injection on the basis of control groups. The mechanical ventilation of the two groups was observed and recorded. The pulmonary function of the two groups before and after treatment was recorded. The blood gas levels were measured before and after treatment in both groups. The levels of serum PCT, hs-CRP and MMP-9 were measured before and after treatment. Theincidence of adverse reactions during the treatment of the two groups of patients was recorded. RESULTS The total effective rate was 98.33 % in observation group, which was significanlly higher than 86.67 % in control group （P 〈0.05）. Compared with control group, the time of meehanicaI ventilation, the reuse rate of machine and the time to stay in ICU were reduced, and the success rate of offline was increased （P〈0.05）. After receiving treatment, the FEV1, FEV1/FVC and MVV of both groups increased （P d0.05）. The values of FEV1, FEV1/FVC and MVV in observation group were （1.81±0.51） L, （71.08±8.57）% and （75.14±_5.82）L/min. Compared with the control group, there was a significant increase （P〈0.05）. After treatment, PaO2 and pH increased and PaCO2 decreased in both groups （P〈0.05）. PaO2, PaCO2 and pH of observation group were （73.48±7.51） mmHg, （ 56.81± 6.43 ） m m Hg and （7.61± 0.50 ）. PaO2 and p H values were significantly higher than those of control group （P〈0.05）, and PaCO2 value was significantly lower than that of control group （P〈0.05）. After treatment, ser- um PCT, hs CRP and MMP-9 levels decreased in both groups （P〈0.05）. The levels of serum PCT, hs-CRP and MMP-9 of observation group were （0.57±0.08）μg/L, （13.21±3.02） mg/L and （0.30±0.04） μg/L, which were significantly lower than those of control group （P〉0.05）. During the treatment period, there were serious adverse reactions in the two groups, 1 case of mild abdominal pain ahd 1 case of diarrhea occurred in observation group, and 2 cases of chest tightness occurred in control group.CONCLUSION Shenqi Fuzheng injection is effective in the treatment of lung cancer with obstructive pulmonary infections and can significantly reduce the concentrations of serum PCT, hs-CRP and MMP-9 of patients.